Efficacy of blanket treatment of cows and heifers with an internal teat sealant in reducing the risk of mastitis in dairy cattle calving on pasture

AIM: To evaluate the benefit of blanket treatment of all milking cows at drying-off and all replacement heifers one month prior to the planned start of mating with an internal teat sealant on the incidence of mastitis, and somatic cell counts (SCC), postpartum in a 650-cow herd with a mastitis incidence in early lactation of 15% in cows and 26% in heifers. METHODS: Prior to drying-off, lactating cattle were divided on the basis of SCC and mastitis history. Cattle with records of individual SCC >150,000 cells/ml or mastitis in the previous lactation were treated with a cloxacillin-based dry-cow therapy (DCT), while the remaining cattle received no antibiotics. Cattle in each of the two groups were then randomly assigned to receive either an internal teat sealant or no further treatment. Additionally, one month prior to the planned start of calving the rising 2-year-old heifers were also randomly assigned to receive either an internal teat sealant or no treatment. All clinical mastitis cases were recorded for the first 10 weeks after the start of calving, while SCC were measured on three occasions during the subsequent lactation. RESULTS: Data were available from 466 cows and 206 heifers; treatment with the internal teat sealant significantly reduced the incidence of mastitis in both groups. For cows, the reduced risk of mastitis due to treatment with the teat sealant was not significantly different between cows, which, based on their mastitis history, required dry-cow antibiotics and those which did not. There was no effect of teat sealant on the mean SCC of any group at any time-point. CONCLUSIONS: On this farm, treatment of all cows and heifers prior to parturition with an internal teat sealant significantly reduced the risk of clinical mastitis. The benefits of an internal teat sealant were the same when used in combination with antibiotics in cows with a history of mastitis as when used alone in cows with no such history. CLINICAL RELEVANCE: These data support the proposition that blanket treatment with an internal teat sealant of all cows due to enter the milking herd can be a useful method of mastitis control. They also suggest that combined therapy with dry-cow antibiotics and internal teat sealants can be beneficial under New Zealand conditions. More detailed research on more farms in more areas of New Zealand is required to confirm these suggestions.     

Comparison of cephalonium alone and in combination with an internal teat sealant for dry cow therapy in seasonally calving dairy cows

AIM: To assess the effect of combining an internal teat sealant (ITS) and a long-acting cephalonium-based dry cow therapy (DCT) on the prevalence of cows with a somatic cell count (SCC) >150,000 cells/mL 60–80 days after calving, and the incidence of clinical mastitis diagnosed by farm staff in the first 100 days after calving.

METHODS: Cows from a spring-calving, pasture-based, dairy farm in the South Canterbury region of New Zealand were randomly allocated to receive cephalonium DCT (n=289) or cephalonium and internal teat sealant (n=304) at the end of lactation. Cows were inspected twice daily by farm staff during the dry period and following calving for signs of mastitis. Individual SCC were determined from herd tests conducted in the previous lactation and following calving. Logistic regression models were used to determine relationships with the prevalence of cows with a SCC >150,000 cells/mL after calving, and survival analysis was used to model time to the first case of clinical mastitis following calving at the cow and quarter level.

RESULTS: The OR for a cow with a SCC >150,000 cells/mL after calving, including age and individual SCC in the preceding lactation in the model, was 0.53 (95% CI=0.32–0.89) for cows treated with combination therapy compared to cows receiving cephalonium (p=0.017). At the cow level, including age and preceding SCC in the model, the hazard ratio for diagnosis of clinical mastitis by farm staff in the first 100 days of lactation was 0.60 (95% CI=0.39–0.98) for cows treated with combination therapy compared to cows receiving cephalonium (p=0.04). At the quarter level, the hazard ratio for diagnosis of clinical mastitis, with age included in the model, was 0.41 (95% CI=0.23–0.74) for the combination therapy compared to cephalonium alone (p<0.001).

CONCLUSIONS: The combination of internal teat sealant and cephalonium DCT was more effective than cephalonium alone at reducing clinical mastitis diagnosed by farm staff in the 100 days after calving, and the prevalence of cows with a SCC >150,000 cells/mL 60–80 days after calving.

CLINICAL RELEVANCE: This study adds to the evidence that the prevention of intra mammary infections throughout the dry period and up to calving by using combination therapy is important in reducing the incidence of farmer-diagnosed clinical mastitis and prevalence of cows with a SCC >150,000 cells/mL 60–80 days after calving.     

Effect of treatment with an internal teat sealant at drying-off in cows wintered on forage crops in New Zealand on clinical mastitis and somatic cell counts

AIMS: To determine the impact of treatment with internal teat sealant (ITS) compared to no treatment at drying-off on the incidence of clinical mastitis (CM) during the dry period and 84 days after calving, and the prevalence of cows with somatic cell counts (SCC) ≥200,000?cells/mL at the first lactation herd test, for cows wintered on forage crops.

METHODS: In four dairy herds in the South Island of New Zealand, cows with no history of CM or individual SCC >100,000?cells/mL during the 2015–16 season were randomly assigned to treatment with ITS in each quarter (ITS group) at drying-off or no treatment (Control group). Cows were otherwise treated similarly, wintered on forage crops and transferred to pasture for calving and lactation. Cows were monitored over the dry period and for 84 days after calving, and any case of CM recorded. Individual SCC were recorded at the first herd test after calving.

RESULTS: Between drying-off and 84 days after calving 36/470 (7.7%) cows in the ITS groups and 73/442 (16.5%) cows in the Control group were diagnosed with CM (RR=0.46; 95% CI=0.26–0.73). The final multivariable logistic regression model included an interaction between treatment group and length of dry period. For a Friesian/Jersey cow, aged 4–8 years, with a dry period of 30–80 days, dried off without ITS, the probability of CM in the study period was 0.12 (95% CI=0.09–0.16), and for such a cow treated with ITS the probability was 0.07 (95% CI=0.05–0.10). For an equivalent cow, with a dry period of 81–140 days, which was untreated, the probability was 0.21 (95% CI=0.14–0.29), and for such a cow treated with ITS it was 0.05 (95% CI=0.02–0.11). At the first herd test after calving 77/383 (20.1%) cows in the Control group and 57/425 (13.4%) cows in the ITS group had SCC ≥200,000?cells/mL (RR=1.51; 95% CI=1.10–2.06).

CONCLUSIONS AND CLINICAL RELEVANCE: For these farms, treatment of cows with no history of elevated SCC or CM with ITS at drying-off halved the incidence of CM between drying-off and 84 days after calving, and reduced by 33% the proportion of cows with SCC≥200,000 at the first herd test after calving, compared with untreated cows. Treatment with ITS reduced the risk of CM proportionally more for cows with a dry period of 81–140 days than for cows with a shorter dry period.     

Comparative efficacy of three dry-cow antibiotic formulations in spring-calving New Zealand dairy cows

AIM: To evaluate the efficacy of a dry-cow antibiotic preparation containing cloxacillin plus ampicillin in a formulation that gives a 10-week duration of action, in comparison to products containing cephalonium (10-week action) or cloxacillin alone (7-week action). METHODS: A total of 493 cows were selected from 6 spring-calving dairy herds in the Manawatu region of New Zealand, according to the criteria of the SAMM plan, to receive intramammary antibiotic therapy at the end of lactation (drying off). Cows were randomly allocated to receive 1 of the 3 dry-cow antibiotic products under investigation. Cows were examined twice during the dry period and twice daily during the first 10 days of their subsequent lactation for the presence of mastitis. Milk samples were collected from individual quarters at the time of drying off and at 7 and 28-35 days after calving, for determination of milk somatic cell counts (SCC). Bacteriology was carried out on milk samples taken from cows that developed mastitis during the first 10 days after calving. RESULTS: No cows developed mastitis during the dry period. Sixteen cows developed clinical mastitis within 10 days of calving; there was no difference in incidence between treatments. Streptococcus uberis was the most commonly isolated organism. Mean SCC on Day 7 were lower (p = 0.019) in cephalonium-treated quarters (189.9+/-28.4 x 10(3) cells/ml) than in cloxacillin-treated quarters (388.7+/-71.2 x 10(3) cells/ml); values in quarters receiving cloxacillin plus ampicillin were intermediate (252.0+/-47.0 x 10(3) cells/ml). SCC were similar between treatment groups on Day 28-35. CONCLUSIONS: The use of a combination of cloxacillin plus ampicillin was effective for the prevention of mastitis during the dry and peri-calving-periods in pastured dairy cattle.     

Skin sensitivity to tuberculins in cattle vaccinated against Johne's disease

Aim: To evaluate the efficacy of a dry-cow antibiotic preparation containing cloxacillin plus ampicillin in a formulation that gives a 10-week duration of action, in comparison to products containing cephalonium (10-week action) or cloxacillin alone (7-week action).

Methods: A total of 493 cows were selected from 6 spring-calving dairy herds in the Manawatu region of New Zealand, according to the criteria of the SAMM plan, to receive intramammary antibiotic therapy at the end of lactation (drying off). Cows were randomly allocated to receive 1 of the 3 dry-cow antibiotic products under investigation. Cows were examined twice during the dry period and twice daily during the first 10 days of their subsequent lactation for the presence of mastitis. Milk samples were collected from individual quarters at the time of drying off and at 7 and 28-35 days after calving, for determination of milk somatic cell counts (SCC). Bacteriology was carried out on milk samples taken from cows that developed mastitis during the first 10 days after calving.

Results: No cows developed mastitis during the dry period. Sixteen cows developed clinical mastitis within 10 days of calving; there was no difference in incidence between treatments. Streptococcus uberis was the most commonly isolated organism. Mean SCC on Day 7 were lower (p = 0.019) in cephalonium-treated quarters (189.9 ± 28.4 × 10³ cells/ml) than in cloxacillin-treated quarters (388.7 ± 71.2 x 10³ cells/ml); values in quarters receiving cloxacillin plus ampicillin were intermediate (252.0 ± 47.0 × 10³ cells/ml). SCC were similar between treatment groups on Day 28–35.

Conclusions: The use of a combination of cloxacillin plus ampicillin was effective for the prevention of mastitis during the dry- and peri-calving-periods in pastured dairy cattle.     

Effect of dry period length on the effect of an intramammary teat sealant on the risk of mastitis in cattle treated with antibiotics at drying off

AIM: The aim of this study was to evaluate, under farm conditions, the use of a teat sealant in addition to whole herd dry cow antibiotic therapy on the risk of clinical mastitis in dairy cattle at pasture, and to evaluate the impact of dry period length on that risk and the impact of the teat sealant on that risk.

METHODS: Dairy cows in three herds which used routine whole herd antibiotic therapy were randomly assigned to receive either treatment with an internal teat sealant (n=322) or no additional treatment (n=313) at drying-off between March and May 2010. All clinical mastitis cases during the dry period and to the end of the subsequent lactation were recorded by farm staff; factors affecting risk of clinical mastitis were then analysed using a Cox proportional hazards model.

RESULTS: Median duration of the dry period was 112 days with >25% of cows having a dry period >130 days. The incidence risk of mastitis during lactation for cows treated with teat sealant was 9.9 (95% CI=6.9–13.7) cases per 100 cows compared with 17.9 (95% CI=13.8–22.6) cases per 100 cows for cows treated with antibiotic alone. The addition of a teat sealant to dry cow antibiotic therapy decreased the risk of clinical mastitis only in the first 33 days after calving (Hazard risk 0.24 (95% CI=0.12–0.48)). Length of dry period did not significantly affect the risk of clinical mastitis, or the effect of adding teat sealant to dry cow antibiotic therapy on the risk of clinical mastitis.

CONCLUSIONS: In these herds where, based on the mastitis history, whole herd antibiotic therapy had been recommended, the use of a teat sealant significantly reduced the risk of clinical mastitis. This effect was limited to the first 33 days after calving; subsequently there was no significant effect of treatment. There was no effect of dry period length on risk of clinical mastitis, nor any significant interaction with treatment.

CLINICAL RELEVANCE: Combination therapy with teat sealant and antibiotic was effective under New Zealand conditions in herds using whole herd antibiotic treatment at drying off. Teat sealant reduced risk of clinical mastitis in cattle with dry periods substantially longer than 100 days, and there was no evidence that this effect changed as dry period length increased.     

Comparison of the efficacy of cloxacillin alone and cloxacillin combined with an internal teat sealant for dry-cow therapy

All the quarters in the cows with high somatic cell counts in 10 herds were treated at drying off with either 600 mg cloxacillin or 600 mg cloxacillin and 4 g of an internal teat sealant containing 65 per cent bismuth subnitrate. The quarters were sampled daily for bacteriological tests for the three days before drying off and twice after calving to establish whether they were infected. Clinical mastitis cases were monitored from drying off until 100 days after calving. The odds of a quarter being bacteriologically negative after calving or developing clinical mastitis in the first 100 days after calving were investigated by multilevel logistic regression. The quarters treated with the internal sealant and cloxacillin were significantly more likely to be bacteriologically negative in the immediate period after calving and were significantly less likely to suffer clinical mastitis during the first 100 days after calving than the quarters treated with cloxacillin alone. There was more variation between cows than between herds in the underlying risk of an infection after calving, but there was more variation between herds than between cows in the underlying risk of clinical mastitis during the 100 days after calving.     

The use of high somatic cell count prevalence in epidemiologic investigations of mastitis control practices

A series of least-squares analytical models were developed in a cross-sectional epidemiologic study of the observed variability in within-herd high somatic cell count (SCC) prevalence, a measure of mastitis prevalence in dairy herds. The dependent variable, high SCC prevalence, was calculated as the 12-month rolling herd average percentage of lactating cows with milk SCC in excess of 283 000 cells ml⁻¹.

The first analysis involved the results of a bacteriologic survey of bulk-tank milk samples for the presence of Streptococcus agalactiae and coagulase-positive staphylococci, the two most common contagious intramammary pathogens. The presence of either pathogen in bulk-tank samples was associated with significantly higher high SCC prevalence.

The second analysis involved responses to a questionnaire concerning management and mastitis control practices. Both the practices of post-milking teat dopping and dry-cow antibiotic therapy were associated with significantly lower high SCC prevalence.

The third analysis combined the data collected for the first two analyses so that the independent variables included both bulk-tank bacteriologic results and management and mastitis control practices. This model was able to explain a greater proportion of the variability in high SCC prevalence than either of the other two models. There were three variables associated with significant decreases in high SCC prevalence namely the absence of Streptococcus agalactiae in the bulk tank milk, the adoption of post-milking teat dipping and the practice of dry-cow antibiotic therapy of all cows.

Milk somatic cell counting is now widely accepted and practiced in many countries, and individual-cow SCC data are available from large numbers of herds at a minimal expense. By corroborating the role of post-milking teat dipping and dry-cow antibiotic therapy in mastitis control programs, this study establishes the usefulness of high SCC prevalence data for epidemiologic studies of mastitis control practices.     

The prophylactic effect of a dry-cow antibiotic against Streptococcus uberis

The prophylactic use of a dry-cow antibiotic for reducing the incidence of mastitis due to Streptococcus uberis was studied in four seasonally calving dairy herds involving 378 cows. The treatment was a long-acting dry-cow antibiotic preparation administered immediately after the last milking of lactation. New intramammary infections were identified by comparing the bacteriological status of quarters at drying off with that after calving, or through manual udder palpation during the dry period. The administration of dry-cow antibiotic to uninfected quarters at drying off reduced the overall incidence of new infections with Streptococcus uberis from 12.3% for untreated quarters to 1.2% of quarters (p<0.01). The reduction was significant (p<0.01) for both dry-period and post-calving infections. The susceptibility of uninfected quarters to new infection by Streptococcus uberis appeared to be unrelated to the infection status of a cow at drying off. Clinical infections during the dry period were most prevalent (97%) in quarters identified as having open teat canals. Fewer open teat canals (p<0.05) were observed among antibiotic treated quarters over the first 4 weeks of the dry period. Treated quarters had a lower (p<0.05) incidence of new clinical infection during the ensuing lactation and lower somatic cell counts. This did not affect production levels of milk, milk fat or protein. The results clearly indicated a prophylactic benefit for the dry cow antibiotic treatment against new Streptococcus uberis infections during the dry period.     

The prophylactic effect of a dry-cow antibiotic against Streptococcus uberis

The prophylactic use of a dry-cow antibiotic for reducing the incidence of mastitis due to Streptococcus uberis was studied in four seasonally calving dairy herds involving 378 cows. The treatment was a long-acting dry-cow antibiotic preparation administered immediately after the last milking of lactation. New intramammary infections were identified by comparing the bacteriological status of quarters at drying off with that after calving, or through manual udder palpation during the dry period. The administration of dry-cow antibiotic to uninfected quarters at drying off reduced the overall incidence of new infections with Streptococcus uberis from 12.3% for untreated quarters to 1.2% of quarters (p<0.01). The reduction was significant (p<0.01) for both dry-period and post-calving infections. The susceptibility of uninfected quarters to new infection by Streptococcus uberis appeared to be unrelated to the infection status of a cow at drying off. Clinical infections during the dry period were most prevalent (97%) in quarters identified as having open teat canals. Fewer open teat canals (p<0.05) were observed among antibiotic treated quarters over the first 4 weeks of the dry period. Treated quarters had a lower (p<0.05) incidence of new clinical infection during the ensuing lactation and lower somatic cell counts. This did not affect production levels of milk, milk fat or protein. The results clearly indicated a prophylactic benefit for the dry cow antibiotic treatment against new Streptococcus uberis infections during the dry period.     

Subclinical ketosis in post-partum dairy cows fed a predominantly pasture-based diet: defining cut-points for diagnosis using concentrations of beta-hydroxybutyrate in blood and determining prevalence

AIMS: Firstly, to define, in dairy cows in the first 5 weeks post-calving fed a predominantly pasture-based diet, cut-points of concentrations of beta-hydroxybutyrate (BHBA) in blood, above which there were associations with purulent vaginal discharge (PVD), reduced pregnancy rates (PR) and decreased milk production, in order to better define subclinical ketosis (SCK) in such cattle; and secondly, to determine the prevalence, incidence and risk factors for SCK.

METHODS: An observational field study was conducted in 565 cows from 15 spring-calving and predominantly pasture-fed dairy herds in two regions of New Zealand during the 2010– 2011 dairy season. Within each herd, a cohort of randomly selected cows (approximately 40 per herd) was blood sampled to determine concentrations of BHBA on six occasions at weekly intervals starting within 5 days of calving. The key outcome variables were the presence/absence of PVD at 5 weeks post-calving, PR after 6 weeks (6-week PR) and after the completion of the breeding season (final PR), and mean daily milk solids production.

RESULTS: Two cut-points for defining SCK were identified: firstly concentration of BHBA in blood ≥1.2?mmol/L within 5 days post-calving, which was associated with an increased diagnosis of PVD (24 vs. 8%); and secondly concentration of BHBA in blood ≥1.2?mmol/L at any stage within 5 weeks post-calving, which was associated with decreased 6-week PR (78 vs. 85%). The mean herd-level incidence of SCK within 5 weeks post-calving was 68 (min 12; max 100)% and large variations existed between herds in peak prevalence of SCK and the interval post-calving at which such peaks occurred. Cows >8 years of age and cows losing body condition were at increased risk of SCK within 5 weeks of calving.

CONCLUSIONS: Cows with concentration of BHBA in blood ≥1.2?mmol/L in early lactation had a higher risk of PVD and lower 6-week PR. Cow and herd-level prevalence of SCK varied widely in early lactation.

CLINICAL RELEVANCE: Subclinical ketosis is common and is significantly associated with reproductive performance in mainly pasture-fed New Zealand dairy cattle. Controlling SCK may therefore result in improvements in herd reproductive performance. However considerable variation exists among herds in the incidence of SCK and in the timing of peak prevalence which means that herd-specific monitoring programmes are required to define herd SCK status accurately.     

Efficacy of controlled-release capsules containing monensin for the prevention of subclinical ketosis in pasture-fed dairy cows

AIMS: To determine the effectiveness of intra-rumenal controlled release capsules (CRC) containing 32?g of monensin administered pre-calving to reduce the cumulative incidence of subclinical ketosis (SCK) in mainly pasture-fed dairy cows.

METHODS: Cows (n=837) due to calve in the first 6 weeks of the spring calving period were enrolled from four commercial herds in the Waikato region of New Zealand in a blinded, randomised, negative-controlled field trial. Three weeks before the start of the calving period cows were randomly allocated to receive either no treatment (control) or a single CRC containing monensin and then blood sampled on two occasions, 7 days apart within 12 days following calving for measurement of concentrations of beta hydroxybutyrate (BHBA) in blood. Cows were diagnosed with SCK if the concentration of BHBA in blood in either of these samples was ≥1.2?mmol/L.

RESULTS: Fewer treated cows were diagnosed with SCK within 12 days post-calving than control cows (144/340 (42.4%) vs. 192/336 (57.1%); p<0.001). There was no interaction between treatment group and age, breed or herd of origin. From the final multivariable model it was estimated that treatment with CRC containing monensin reduced the absolute cumulative incidence of SCK by 17.9 (95% CI=9.2–25.8)% compared to no treatment.

CONCLUSIONS: Treatment with a CRC containing monensin >10 days prior to calving reduced the cumulative incidence of SCK of pasture-based dairy cows in commercial dairy herds within 12 days post-calving.

CLINICAL RELEVANCE: Administration pre-calving of an intra-rumenal bolus containing monensin can be considered as one of a range of management options for the control of SCK in early lactation.     

The management and treatment of environmental streptococcal mastitis.

Environmental streptococci are responsible for at least one third of all cases of clinical mastitis, with the proportion varying widely between herds. Each dairy farmer should know the etiology of mastitis in the herd to allow for appropriate management. Control requires lowering the prevalence of infection, and includes shortening the duration of and preventing new infections. Prompt and aggressive treatment of clinical cases may achieve a high clinical and bactriologic rate of cure. Dry-cow treatment remains highly effective in eliminating infection. Prophylactic dry-cow treatment remains of substantial benefit in preventing new intramammary infections and clinical mastitis. An internal teat sealant has shown a comparable effect in uninfected cows in field studies. Management of exposure to environmental streptococci is essential and requires assessment of the risk of exposure (especially in bedding and other lying areas), reduction of teat-end contamination, and good hygienic milking practices. The key is in the quality of application of management.     

Effect of application of an external teat sealant and/or oral treatment with a monensin capsule pre-calving on the prevalence and incidence of subclinical and clinical mastitis in dairy heifers

AIM: To assess the effect of applying an external teat sealant or a slow-release intraruminal monensin capsule pre-calving on the prevalence and incidence of subclinical or clinical mastitis in dairy heifers post-calving. METHODS: The studies were undertaken in 13 herds. In two herds application of an external teat sealant was compared with a negative control; in nine herds treatment with monensin was compared with controls, and in two herds treatments were applied in a 2 x 2 factorial design. Heifers were randomly assigned within herd to be treated with a slow-release intraruminal device containing 32 g monensin (n=383), or left as untreated controls (n=389), approximately 30 days before the start of the spring calving period; or to be treated with a latex external teat sealant (n=206) when calving was impending, or be left as untreated controls (n=205). Milk samples were collected from each gland between 0 and 5 days after calving and from any gland diagnosed with clinical mastitis. The effect of the treatments on the prevalence of intramammary infection (IMI), i.e. subclinical mastitis, and clinical mastitis were initially analysed at the univariate level, with associated variables (p<0.2) being used in construction of multivariable models. RESULTS: The prevalence of IMI was 18.4% at the gland level, and coagulase-negative staphylococci followed by Streptococcus uberis were the most common isolates. Treatment with an external teat sealant reduced the prevalence, compared with controls, of any IMI (12.1 (SE 1.7)% vs 16.5 (SE 2.1)%, respectively; p=0.05) or IMI caused by a major pathogen (3.8 (SE 0.8)% vs 6.0 (SE 1.1)%, respectively; p=0.05). Monensin treatment did not affect the prevalence of any IMI (p=0.68) or IMI due to a major pathogen (p=0.11). The cumulative incidence of clinical mastitis was 14.2%. Neither monensin treatment (p=0.47) nor application of an external teat sealant (p=0.71) altered the risk of clinical mastitis. There was no interaction between the monensin and external teat sealant in the two herds where the treatments were applied in a 2 x 2 factorial design. CONCLUSIONS: Application of an external teat sealant resulted in a lower prevalence of any IMI and of an IMI caused by a major pathogen. Despite monensin reducing the mobilisation of body tissue and the risk of subclinical ketosis, it had no effect on the prevalence or incidence of IMI or clinical mastitis. CLINICAL RELEVANCE: Application of an external teat sealant is an option for reducing the prevalence of IMI in pasture fed dairy heifers.     

A comparative field trial of cephalonium and cloxacillin for dry cow therapy for mastitis in Australian dairy cows

OBJECTIVE: To investigate and compare the therapeutic efficacy of dry cow agents containing either cephalonium or cloxacillin within Australian dairy herds. DESIGN: A treatment-control trial. METHODS: Milk from infected quarters of cows with high somatic cell counts in milk on eight Australian dairy farms was cultured to identify bacterial pathogens. Cows were randomly assigned to treatment groups and one group was treated with cephalonium at drying off and the other group was treated with cloxacillin at drying off. Milk samples from infected quarters were collected immediately after calving and were cultured for pathogens. The effect of treatment on bacteriological cure was examined and somatic cell counts from infected cows from the first two herd tests after calving were examined for a treatment effect. On four farms, milk samples were collected for culture from all cases of clinical mastitis identified within the first 7 days after calving. The effect of treatment upon incidence of clinical mastitis after calving was examined. RESULTS: There was no significant difference between treatments on quarter cure rates for new infections, for chronic infections and for infections with Staphylococcus aureus, Streptococcus agalactiae and Streptococcus uberis. Infected quarters treated with cephalonium had a significantly higher cure rate than quarters treated with cloxacillin when Corynebacterium bovis and Staphylococcus epidermids were included as pathogens combined (80.3% versus 70.7%). There was no significant difference between the treatments on somatic cell counts of infected cows at the first two herd tests after calving. There was no difference between treatments on the incidence of clinical mastitis in the first 7 days after calving.     

Teat endoscopy (theloscopy) for diagnosis and therapy of milk flow disorders in dairy cows.

Teat endoscopy (theloscopy) is a useful technique for diagnosis and therapy of covered teat injuries. Minimal invasive theloscopic surgery may help to restore milk flow, milk yield, and SCC of the affected quarter.Infection with pathogens may not change significantly, however. Cows treated as described may yield as much milk as their herdmates at a slightly increased udder SCC and stay as long in the herd as their herdmates. Theloscopy also may be used for diagnosis and therapy of various other teat disorders.     

Effect of using an internal teat sealant at drying-off in cows wintered on forage crops in New Zealand on culling in the dry period and early lactation

AIMS: To determine the impact of treatment with internal teat sealant (ITS) compared to no treatment at drying-off on culling during the dry period and 90 days after calving, for cows wintered on forage crops.

METHODS: In four dairy herds in the South Island of New Zealand, cows with no history of clinical mastitis or somatic cell counts >100,000 cells/mL during the 2015–16 season were randomly assigned to treatment with ITS in each quarter (ITS group) or no treatment (Control group). Cows were otherwise treated similarly, wintered on forage crops and transferred to pasture for calving and lactation. Culling was defined as an unplanned exit from the herd, including cows sold for slaughter, cows slaughtered for salvage value and cows that died on farm. Culls and cull dates were recorded between drying-off and 90 days after calving.

RESULTS: Between drying-off and 90 days after calving 24/491 (4.9%) cows in the ITS group and 45/473 (9.5%) cows in the Control group were culled (RR=0.51; 95% CI=0.75–0.83), and between 30 days before calving and 90 days after calving 20/491 (4.1%) cows in the ITS group and 40/473 (8.5%) cows in the Control group were culled (RR=0.48; 95% CI=0.29–0.81). In the final multivariable logistic regression model, adjusting for dry-period length, cow age, breed and farm, the OR for culling in the study period was 0.43 (95% CI=0.23–0.81) for cows in the ITS compared with the Control group. For a Friesian/Jersey cow, aged 4–8 years, with a dry period of 30–80 days, dried-off without ITS, the probability of culling in the study period was 0.10 (95% CI=0.06–0.16), and for such a cow treated with ITS the probability was 0.05 (95% CI=0.03–0.08).

CONCLUSIONS AND CLINICAL RELEVANCE: In these four herds, the use of ITS at drying-off reduced the incidence of culling between drying-off and 90 days after calving. The use of ITS at drying-off in cows prior to wintering on forage crops may provide additional benefit to farmers through reduced incidence of culling and should be considered in any cost–benefit analysis of its use.     

Cheyletiella parasitivorax infestation of cats associated with skin lesions of man

Two dry-cow therapy products were evaluated in seven factory-supply dairy herds in the Waikato area. A product containing neomycin sulphate and the benzathine salt of penicillin (Neopen D.C. White; Smith-Biolab) was used in five herds, and one containing benzathine cloxacillin (Orbenin, Beecham) was used in two herds. Non-treated control cows were included in each herd. Both products were effective in eliminating intramammary infections with Staphylococcus aureus, Streptococcus uberis, and Streptococcus agalactiae. Efficacy of dry-cow therapy against S. aureus was 83.8% and 85.2% respectively. Spontaneous cure rate among controls was 30.8% for S. aureus during the dry period. Spontaneous cure rate for Str. uberis was 50%, while dry-cow therapy eliminated 100% and 77.8%, respectively, for the two products. Dry-cow therapy with either product eliminated more than 90% of Str. agalactiae infections while spontaneous cure rate was only 28.6%. These results further support the effectiveness of dry-cow therapy in reducing the level of subclinical mastitis in dairy herds by shortening the duration of intramammary infections.     

Infertility and abortion among first-lactation dairy cows seropositive or seronegative for Leptospira interrogans serovar hardjo.

OBJECTIVE: To estimate the extent to which exposure to Leptospira hardjo before or at the time of first parturition was associated with infertility and abortion during the first lactation among dairy cows that had not been vaccinated for > or = 12 months. ANIMALS: 207 first-lactation cows from a herd of 2,000 lactating cows. PROCEDURE: Cows were tested for antibodies to L hardjo within 40 days after calving. Time from calving to first breeding, time from calving to conception, number of breedings per conception, and risk of abortion were compared between cows seropositive for L hardjo and cows that were seronegative. RESULTS: For the 9 (4.3%) cows that were seropositive for L hardjo, median time from calving to conception (132.6 days) was significantly longer than time for seronegative cows (95.4 days). Cows that were seropositive were twice as likely (relative risk, 2.07) to fail to conceive as seronegative cows. Mean number of breedings required per conception for seropositive cows (3.4) was significantly higher than that for seronegative cows (2.1). The proportion of seropositive cows that aborted was not significantly different from the proportion of seronegative cows that aborted. CONCLUSIONS AND CLINICAL RELEVANCE: Exposure of nonvaccinated dairy cows to L hardjo can be associated with a subsequent reduction in fertility, as indicated by a greater time from calving to conception and higher number of breedings required per conception. The efficacy of leptospiral vaccines should be assessed to determine whether vaccination will minimize herd infertility associated with L hardjo infection.     

A note on effectiveness of dry cow therapy in New Zealand dairy herds

Two dry-cow therapy products were evaluated in seven factory-supply dairy herds in the Waikato area. A product containing neomycin sulphate and the benzathine salt of penicillin (Neopen D.C. White; Smith-Biolab) was used in five herds, and one containing benzathine cloxacillin (Orbenin, Beecham) was used in two herds. Non-treated control cows were included in each herd. Both products were effective in eliminating intramammary infections with Staphylococcus aureus, Streptococcus uberis, and Streptococcus agalactiae. Efficacy of dry-cow therapy against S. aureus was 83.8% and 85.2% respectively. Spontaneous cure rate among controls was 30.8% for S. aureus during the dry period. Spontaneous cure rate for Str. uberis was 50%, while dry-cow therapy eliminated 100% and 77.8%, respectively, for the two products. Dry-cow therapy with either product eliminated more than 90% of Str. agalactiae infections while spontaneous cure rate was only 28.6%. These results further support the effectiveness of dry-cow therapy in reducing the level of subclinical mastitis in dairy herds by shortening the duration of intramammary infections.